We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

AiCuris Drug Letermovir Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus Prophylaxis

News   Feb 14, 2012

 
AiCuris Drug Letermovir Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus Prophylaxis
 
 
Advertisement
 

RELATED ARTICLES

FDA Grants Fast Track Designation to Onvansertib for Second-line Treatment of KRAS-mutated Colorectal Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

READ MORE

New Molecule Stops Drug Cravings in Mice

News

A team from Duke University has developed a synthetic molecule that selectively dampens the physiological rewards of cocaine in mice. This molecule could represent a new class of drugs that may be more specific that currently available medications, with fewer adverse effects.

READ MORE

Trial Investigates Remdesivir–Baricitinib Combo as COVID-19 Treatment

News

Following on from remdesivir’s promising results from previous studies, a new trial is now investigating remdesivir in combination with baricitinib or placebo as a treatment for COVID-19, in a double-blind, randomized trial.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE